On September 8, SBP GROUP rose 3.02% in regular trading, trading at HK$5.64 per share, with turnover of HK$129 million. The move came after the company disclosed positive Phase I clinical trial data for its TQC3721 dry powder inhaler at the European Respiratory Society 2026 annual meeting.

According to filings, the company's subsidiary Chia Tai Tianqing Pharmaceutical Group presented data from two Phase I studies testing the safety and efficacy of TQC3721 in patients with chronic obstructive pulmonary disease (COPD). Adverse event rates were similar across all groups, indicating a favorable safety profile. TQC3721 works through a dual mechanism of bronchodilation and anti-inflammation as a PDE3/4 inhibitor. Notably, the nebulized suspension formulation has already achieved positive results in a Phase IIb study and is currently undergoing Phase III clinical trials in China, having been designated a breakthrough therapy by China's NMPA review center.

The clinical data release follows a strong first half, during which SBP GROUP reported revenue of RMB 19.44 billion, up 10.6% year-over-year, with innovative drug sales surging 44.3% to RMB 8.79 billion. Multiple brokerages including Citi, Daiwa, and Bank of America have maintained buy ratings with target prices ranging from HK$7.1 to HK$10.8.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)